US-based digital health company Livongo Health raised $44.5m on Tuesday in a series C round featuring pharmaceutical company Merck’s Global Health Innovation Fund and auto parts provider Wanxiang America Corporation.
Zaffre Investments, the corporate venturing unit of insurance company Blue Cross Blue Shield of Massachusetts, and Sapphire Ventures, the VC firm spun out of enterprise software producer SAP, also took part in the round.
The corporates were joined by Cowen Private Investments, General Catalyst, Kleiner Perkins Caufield & Byers (KPCB), DFJ, 7wire Ventures, Humana and undisclosed additional investors.
Livongo operates a platform that helps patients manage their chronic conditions, and is initially focusing on diabetes, having developed a connected glucose meter that automatically uploads readings to the cloud. Coaches then offer personalised recommendations based on that data.
The series C capital will support accelerated growth, including the launch of products and services aimed at other chronic conditions.
KPCB, General Catalyst and DFJ previously invested $20m in an April 2015 series B round, after General Catalyst had provided $10m in series A funding in 2014. 7wire Ventures reportedly provided Livongo with seed funding, though further details have not been confirmed.